Author

Gordon Francis

Observed names: Francis Gordon, Gordon Francis Md

Observed institutions: Novartis (Switzerland), St. Michael's Hospital, Cleveland Clinic, Queen Mary University of London, University of Basel, Hospital for Sick Children, University Hospital of Basel, Novartis (India), Novartis (Netherlands), Munich Cluster for Systems Neurology, Novartis (United States), Medical University of Lodz, Blizard Institute, Ludwig-Maximilians-Universität München, Amsterdam UMC Location Vrije Universiteit Amsterdam

OpenAlex ID: A5111635299

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

2010 · Volker Brinkmann, Andreas Billich, et al. · Nature Reviews Drug Discovery · 1,290

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

2011 · Bhupendra Khatri, Frederik Barkhof, et al. · The Lancet Neurology · 220

Long-term effects of fingolimod in multiple sclerosis

2015 · Ludwig Kappos, Paul O'Connor, et al. · Neurology · 191

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis

2015 · Jens Kuhle, Giulio Disanto, et al. · Neurology · 177

Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis

2014 · Goeril Karlsson, Gordon Francis, et al. · Neurology · 161

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis

2015 · Ernst-Wilhelm Radue, Frederik Barkhof, et al. · Neurology · 147

Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis

2013 · Marco A. Zarbin, Lee M. Jampol, et al. · Ophthalmology · 146

Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings

2014 · Ludwig Kappos, Jeffrey Cohen, et al. · Multiple Sclerosis and Related Disorders · 121

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS

2013 · Jeffrey A. Cohen, Frederik Barkhof, et al. · Journal of Neurology · 92

The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis

2014 · Frederik Barkhof, Remko de Jong, et al. · Multiple Sclerosis Journal · 44

Dealing with excess of zeros in the statistical analysis of magnetic resonance imaging lesion count in multiple sclerosis

2012 · Mercier Francois, Chin Peter, et al. · Pharmaceutical Statistics · 10

Fingolimod-Effect on Brain Atrophy and Clinical/MRI Correlations in Three Phase 3 Studies – TRANSFORMS, FREEDOMS and FREEDOMS II (S51.006)

2013 · Jeffrey Cohen, Ernst-Wilhelm Radue, et al. · Neurology · 8

Relapse Is Associated with Residual Deficits in Relapsing-Remitting Multiple Sclerosis: Analysis of FREEDOMS Data (P07.118)

2013 · Gary Cutter, Peter Chin, et al. · Neurology · 5

Assessment of Potential Risk of Progressive Multifocal Leukoencephalopathy with Fingolimod Compared with That of Natalizumab (P01.160)

2013 · Gordon Francis, Frank Dahlke, et al. · Neurology · 1

Works count: 15

Citation count: 2,613

H-index: 10

I10-index: 11